Dorzagliatin

Research use only, not for human use.

Dorzagliatin (HMS-5552, HMS5552) is a novel potent, fourth-generation glucokinase (GK) activator.

Dorzagliatin (HMS-5552, HMS5552) is a novel potent, fourth-generation glucokinase (GK) activator; exerts its antidiabetic effect by inhibiting insulin resistance and increasing insulin sensitivity, significantly increased GK expression; effectively improves GK activity and insulin resistance by targeting both the liver and pancreas in rat T2DM models.Diabetes Phase 2 Clinical(In Vivo):Dorzagliatin (low-dose 10 mg/kg, and high-dose 30 mg/kg; administered intragastrically; daily 8:00 AM for one month) exerts a glucose-lowering effect on the glucose levels in diabetic rats.

——

Animal Model:Male Sprague-Dawley (SD) rats (aged approximately 6–8 weeks and weighing 200-230?g)[2Dosage:Low-dose (10?mg/kg), and high-dose (30?mg/kg) Administration:Administered intragastrically (i.g.); daily (8:00 AM) for one month Result:Exerted a glucose-lowering effect on the glucose levels.

HMS-5552 | HMS5552

Cytoskeleton/Cell Adhesion Molecules

Glucokinase

Glucokinase

Metabolic Disease

Diabetes

1191995-00-2

462.931

C22H27ClN4O5

>98% (HPLC)

10 mM in DMSO

CC(C)C[C@H](N1C(C=C(OC2=CC=CC=C2Cl)C1)=O)C(NC3=NN(C[C@@H](O)CO)C=C3)=O

(2S)-2-[4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl]-N-{1-[(2R)-2,3-dihydroxypropyl]-1H-pyrazol-3-yl}-4-methylpentanamide

(-20℃)

With Ice Pack

≥ 2 years